Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Melanoma Research|August 29, 2024
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital settingRonen Stoff, Svetomir N Markovic, Robert R McWilliams, et al.
Advances in Radiation Oncology|July 26, 2017
18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanomaRyan S Youland, Ann T Packard, Miran J Blanchard, et al.
JCO Clinical Cancer Informatics|April 30, 2024
Identification and Characterization of Immune Checkpoint Inhibitor-Induced Toxicities From Electronic Health Records Using Natural Language ProcessingHannah Barman, Sriram Venkateswaran, Antonio Del Santo, et al.
The Journal of Supportive Oncology|June 28, 2011
A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: North Central Cancer Treatment group study N04CACharles L Loprinzi, Ernie P Balcueva, Heshan Liu, et al.
Cancer|July 22, 2014
Phase III double-blind, placebo-controlled study of gabapentin for the prevention of delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy, NCCTG N08C3 (Alliance)Debra L Barton, Gita Thanarajasingam, Jeff A Sloan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2023
SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal MelanomaLisa A Kottschade, Gregory Russell Pond, Anthony J Olszanski, et al.
Melanoma Research|May 15, 2020
Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patientsJesus Vera Aguilera, Jonas Paludo, Robert R McWilliams, et al.
Immunotherapy|August 6, 2020
Peptide vaccine with glucopyranosyl lipid A-stable oil-in-water emulsion for patients with resected melanomaEric P Grewal, Courtney L Erskine, Wendy K Nevala, et al.
Immunotherapy|November 8, 2023
Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry studyJohn M Kirkwood, Lisa A Kottschade, Robert R McWilliams, et al.
Cancer Medicine|September 8, 2017
Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992-2011Elizabeth Ann L Enninga, Justin C Moser, Amy L Weaver, et al.
Pageof 7